This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pfizer Faces Hazy Future Beyond Lipitor

NEW YORK ( TheStreet) -- Nov. 30 was a big day in the drug industry.

For years it's been marked in the calendars of generic drug makers, Wall Street analysts, and of course, Pfizer (PFE), which lost exclusivity of its most successful drug, the cholesterol fighter Lipitor, on that date.

Now the Dow component is trying to hang onto market share, offering direct mailing of the medication through its Web site and working with insurance companies to offer Lipitor at a discounted price, but Wall Street seems to see this as a losing battle.

"Everyone's numbers have taken Lipitor out," said Miller Tabak's Les Funtleyder, referring to the financial projections of his fellow analysts.

Once a drug's patent expires, there is a six-month exclusivity period where the generic company that files first is able to produce its version. Pfizer made a deal with Watson Phamaceuticals (WPI) where Pfizer makes and supplies Watson with an authorized generic version of Lipitor and Pfizer gets a portion of the sales. This agreement lasts until Nov. 30, 2016.

Pfizer and Watson are competing with Teva Pharmaceutical (TEVA) which has an agreement with Indian drug maker Ranbaxy, who was first to file. Teva gets some of Ranbaxy's profits from the sale of its generic version of Lipitor called Atorvastatin.

Some analysts estimate that Pfizer may be able to hold onto as much as 40% market share in the six-month exclusivity period. At the discounted price that Lipitor is being sold, the company stands to make $1 billion in revenue in that six-month time frame, according to Jeff Jonas, an analyst at Gabelli. Once that six months ends though, Jonas expects Pfizer to see only a "token amount of revenue" coming from consumers who "absolutely insist on the brand."

So what's the future of Pfizer beyond Lipitor?

The company expects "rapid erosion of Lipitor revenue and volume share in the U.S.," according to a spokeswoman, adding that in other markets the decline "may be more gradual."

Pfizer is hoping revenue from new products such as Enbrel, a treatment for autoimmune disorders, Lurica, a fybromyalgia drug, and Prevnar 13, a pediatric vaccine for pneumococcal bacteria, will pick up some of the slack in 2012. It's also counting on topline contributions from the product portfolio of King Pharmaceuticals, which was acquired earlier in 2011.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs